ACTRN12620000986976Recruiting未知
Isolation of CTC (Circulating Tumour Cells) and other rare cells from blood by ISET (Isolation by SizE Of Tumour cells) technology to monitor treatment effectiveness in cancer patients, and to screen for early detection or relapse of cancer.
AProf Dr Karin Ried0 sites5,000 target enrollmentStarted: September 30, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 5,000
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to 80 Years (—)
- Sex
- All
Inclusion Criteria
- •Group 1: Cancer patients
- •a) have previously received (at least 3 weeks ago) or will receive treatment within one week; treatment may include chemotherapy, radiotherapy, hyperthermia, intravenous Vit C, IV Curcumin, or other complementary treatment as prescribed by the treating physician
- •b) for regular monitoring . detection of relapse or tumour progression
- •Group 2: Early detection screening: Patients with a family history of cancer of patients with a chronic disease, advanced age, or as part of a health check
Exclusion Criteria
- •no exclusion
Investigators
Similar Trials
Recruiting
Not Applicable
Determining Circulating Tumour Cells (CTC) and other rare cells in cancer patients and for early detection screeningCancerACTRN12614001143617Dr Karin Ried2,000
Active, not recruiting
Phase 1
CTC-STOP - An investigation into whether a blood test which measures circulating tumour cell (CTC)counts can be used to help doctors decide when a patient should stop their current chemotherapy (docetaxel) treatment compared with standard approaches to guide treatment switch decisions.Advanced Castration Resistant Prostate CancerMedDRA version: 21.0Level: LLTClassification code 10001198Term: Adenocarcinoma of the prostate metastaticSystem Organ Class: 100000004864EUCTR2015-001361-27-GBThe Institute of Cancer Research1,178
Terminated
Phase 3
CTC-STOP Trial: A trial to determine if the use of Circulating Tumour Cell (CTC) counts can direct early discontinuation of docetaxel chemotherapy in patients with metastatic castration resistant prostate cancer (mCRPC), when compared with standard approaches to guide treatment switch decisionsMalignant neoplasm of prostateCancerProstate cancerISRCTN82499869The Institute of Cancer Research1,178
Completed
Not Applicable
Detection of circulating tumor cells (CTC) with novel viral marker (OBP-401) for patients with prostate cancerProstate cancerJPRN-UMIN000010410Department of Urology, Kobe university graduate school of medicine50
Recruiting
Not Applicable
Analysis of circulating tumor cells(CTCs) and clinical significance of CTCs; human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trialnon-small cell lung cancerJPRN-UMIN000024302Osaka University Graduate School of Medicine500